Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 46 of 46 publications.
Skip to main content
Hood K, Bensink M, Ayoub I, Peipert JD, Trachtman H, Wadhwani S, Garbinsky D, Wang J, Zhou X, Bennett L, Choi J, Gong W, Inrig JK, Komers R. Patient-reported outcomes in rare kidney disease clinical trials: sparsentan versus irbesartan. Poster presented at the American Nephrology Nurses Association (ANNA) National Symposium; May 1, 2025. Portland, OR.
Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, Olopoenia A, DeCongelio M, Maculaitis MC, Zhou X. Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data. Kidney Med. 2025 Feb 27;7(5):100988. doi: 10.1016/j.xkme.2025.100988
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18–35 years: a pooled database analysis. Kidney Med. 2025 Jan;7(1):100935. doi: 10.1016/j.xkme.2024.100935
La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796
Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283
Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D, Wang J, Choi J, Bennett L, Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.
Gitomer BY, Chonchol M, Zhou X, Garbinsky D, Wang J, Nunna S, Fernandes AW, Oberdhan D. Kidney stone disease and progression risk in autosomal dominant polycystic kidney disease: a post hoc analysis of OVERTURE. Kidney360. 2024 Sep;5(9):1364-6. doi: 10.34067/KID.0000000000000524
Singer D, Sweeney C, Stempniewicz N, Reynolds M, Garbinsky D, Poston S. Knowledge, attitudes, and practices regarding herpes zoster vaccination among specialists. Popul Health Manag. 2024 Aug;27(4):231-40. doi: 10.1089/pop.2023.0284
Perrone RD, Nunna S, Gandhi HK, Fernandes AW, Garbinsky D, Zhou X. Kidney function decline in autosomal dominant polycystic kidney disease (ADPKD) patients: assessment of real world effectiveness of tolvaptan. Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW. Pooled data analysis of the effect of tolvaptan in patients aged 18-35 years with autosomal dominant polycystic kidney disease. Poster presented at the PKD Connect Conference 2023; June 23, 2023. Denver, CO.
La EM, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Knowledge, attitudes, and perceptions of respiratory syncytial virus (RSV) among U.S. adults with diabetes. Poster presented at the ADA 2023 Conference; June 24, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(Suppl 1). doi: 10.2337/db23-524-P
Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus (RSV) knowledge, attitudes, and perceptions among adults with chronic pulmonary conditions in the US. Poster presented at the ATS American Thoracic Society 2023; May 19, 2023. Washington, DC.
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
La E, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among older adults in the United States. Poster presented at the 12th International RSV Symposium; September 29, 2022. Belfast, Ireland.
Chebib FT, Zhou X, Garbinsky D, Davenport E, Sasikiran N, Oberdhan O, Fernandes A. Pooled data analysis of the long-term effect of Tolvaptan in patients between 56 and 65 years with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Poster presented at the National Kidney Foundation Spring Clinical Meetings; April 6, 2022. Boston, MA.
Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905
Li D, Darden C, Sayeed S, Jackson L, Garbinsky D, Osman N. Patient-reported clinical and productivity outcomes from the longitudinal telotristat ethyl treatment registry. Poster presented at the 2021 Virtual Annual Symposium of the North American Neuroendocrine Tumor Society (NANETS); November 3, 2021.
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. National and state-level composite completion of recommended vaccines among adolescents in the United States, 2015-2018. J Adolesc Health. 2021 Nov;69(5):762-8. doi: 10.1016/j.jadohealth.2021.07.020
Gold BD, Goodwin B, Davis K, Sweeney C, Garbinsky D, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Perceptions of disease stigma in adolescents and adults with eosinophilic esophagitis in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176-7. doi: 10.14309/01.ajg.0000774072.42679.92
Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021 Sep 7;5(1):82. doi: 10.1186/s41687-021-00355-5
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021 May 6;39(19):2660-7. doi: 10.1016/j.vaccine.2021.03.071
Taylor MH, Leboulleux S, Panaseykin S, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life (HRQoL) analyses from study 211: a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN). Poster presented at the 46th Congress of European Society for Medical Oncology (ESMO); September 16, 2021. [abstract] Ann Oncol. 2021; 32(suppl_5):S1205-10. doi: 10.1016/annonc/annonc715
Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057
Hunter S, Garbinsky D, La EM, Poston S, Hogea C. Impact of state of residence on adult vaccination uptake: a multilevel modeling approach. Presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Ghaswalla PK, Garbinsky D, Poston S, Hunter S, Novy P, La EM. Correlates of and disparities in meningococcal B vaccination coverage among 17-year-olds in the United States: a pooled analysis of 2016-2018 National Immunization Survey-Teen. Poster presented at the 2020 Virtual American Academy of Pediatrics National Conference; October 2, 2020.
Darden C, Joish VN, Price MA, Garbinsky D, Schwartz S, Warner C, Wason S, Lapuerta P. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the XERMELO patient registry. Poster presented at the NANETS 2020 Multidisciplinary Net Medical Virtual Symposium; October 2, 2020.
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Individual and state-level factors associated with receipt of multiple recommended adolescent vaccines in the United States. Presented at the IDWeek 2020 Virtual Conference; October 2020.
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Zhou X, Davenport EK, Ouyang J, Krasa H, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across a pooled database of multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical studies. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):663.
Hudiburgh L, Garbinsky D. Data visualization: bringing data to life in an introductory statistics course. J Stat Educ. 2020;28(3):262-79. doi: 10.1080/10691898.2020.1796399
Darden C, Ray D, Goldstein G, Goss D, Garbinsky D, Bennett L, Price M, Thota R. Satisfaction survey of administration modes for Long-Acting (LA) Somatostatin Analog (SSA) therapy in patients with Neuroendocrine Tumors (NETS). Poster presented at the 2019 North American Neuroendocrine Tumor Society (NANETS) Conference; October 3, 2019. Boston, MA.
Zhou X, Garbinsky D, Gnanasakthy A. Methods for reporting the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2019 Duke Industry Statistics Symposium (DISS); April 11, 2019. Durham, NC. Previously presented at the ISPOR 23rd Annual International Meeting.
Zhou X, Eid D, Gnanasakthy A. Methods for reporting the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) data in cancer clinical trials. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S226. doi: 10.1016/j.jval.2018.04.1528
Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Eid D, Bello T. Secukinumab provides greater symptom control in psoriasis-related pain, itching, and scaling compared with previous treatments: evidence from a real-world study in the US. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.